202 327

Cited 3 times in

Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea: Need for Addressing the Ethical Dimensions in Technology Assessment

DC Field Value Language
dc.contributor.author박은철-
dc.date.accessioned2014-12-18T09:03:19Z-
dc.date.available2014-12-18T09:03:19Z-
dc.date.issued2013-
dc.identifier.issn1513-7368-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/87447-
dc.description.abstractThis study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfASIAN PACIFIC JOURNAL OF CANCER PREVENTION-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHDecision Making*-
dc.subject.MESHDrug Costs*-
dc.subject.MESHHumans-
dc.subject.MESHNeoplasms/economics*-
dc.subject.MESHNeoplasms/therapy-
dc.subject.MESHReimbursement Mechanisms/economics-
dc.subject.MESHReimbursement Mechanisms/ethics*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHTechnology Assessment, Biomedical/ethics*-
dc.titlePitfalls in Reimbursement Decisions for Oncology Drugs in South Korea: Need for Addressing the Ethical Dimensions in Technology Assessment-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Preventive Medicine (예방의학)-
dc.contributor.googleauthorEun Cho-
dc.contributor.googleauthorEun-Cheol Park-
dc.contributor.googleauthorMyoung Sheen Kang-
dc.identifier.doi10.7314/APJCP.2013.14.6.3785-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01618-
dc.relation.journalcodeJ00255-
dc.identifier.eissn2476-762X-
dc.identifier.pmid23886183-
dc.subject.keywordDecision Making*-
dc.subject.keywordDrug Costs*-
dc.subject.keywordHumans-
dc.subject.keywordNeoplasms/economics*-
dc.subject.keywordNeoplasms/therapy-
dc.subject.keywordReimbursement Mechanisms/economics-
dc.subject.keywordReimbursement Mechanisms/ethics*-
dc.subject.keywordRepublic of Korea-
dc.subject.keywordTechnology Assessment, Biomedical/ethics*-
dc.contributor.alternativeNamePark, Eun Chul-
dc.contributor.affiliatedAuthorPark, Eun Chul-
dc.rights.accessRightsfree-
dc.citation.volume14-
dc.citation.number6-
dc.citation.startPage3785-
dc.citation.endPage3792-
dc.identifier.bibliographicCitationASIAN PACIFIC JOURNAL OF CANCER PREVENTION, Vol.14(6) : 3785-3792, 2013-
dc.identifier.rimsid34233-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.